Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

S-адеметионин в терапии неалкогольной жировой болезни печени (НАЖБП)

https://doi.org/10.31146/1682-8658-ecg-191-7-68-73

Полный текст:

Аннотация

Представлен обзор экспериментальных и клинических исследований, обосновывающих актуальность включения S-адемитионина в комплексную терапию НАЖБП, направленную на коррекцию оксидативного стресса в гепатоцитах и трансформацию пищевого поведения лиц с избыточной массой тела при развитии депрессивных расстройств.

Об авторах

Н. В. Корочанская
ФГБОУ ВО «Кубанский государственный медицинский университет МЗ РФ»; ГБУЗ «Краевая клиническая больница № 2» МЗ Краснодарского края
Россия


В. М. Дурлештер
ФГБОУ ВО «Кубанский государственный медицинский университет МЗ РФ»; ГБУЗ «Краевая клиническая больница № 2» МЗ Краснодарского края
Россия


М. А. Басенко
ФГБОУ ВО «Кубанский государственный медицинский университет МЗ РФ»; ГБУЗ «Краевая клиническая больница № 2» МЗ Краснодарского края
Россия


Список литературы

1. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology. 2008;134 (6):1641-1654.

2. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J ClinNutr. 2002;76 (5):1183S-1187S.

3. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Perez-Mato I, Sanchez del Pino MM, Corrales FJ, et al. Importance of a deficiency in Sadenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J ClinNutr. 2002;76 (5):1177S-1182S.

4. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31 (2):128-146.

5. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al.ESPEN guidelines on enteral nutrition: liver disease. ClinNutr. 2006;25(2):285-294.

6. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Perez-Mato I, Sanchez delPino MM, Corrales FJ, et al. Importance of a deficiency in adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J ClinNutr. 2002;76 (5):1177S-1182S.

7. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45 (5):1306-1312.

8. Purohit V, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, Kaplowitz N, et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J ClinNutr. 2007;86 (1):14-24.

9. Sanyal AJ. American gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-1725.

10. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease withinsulin resistance. Am J Med. 1999;107 (5):450-455.

11. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of fortytwo patients for up to 21 years. Hepatology. 1990;11 (1):74-80.

12. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45 (6):1366-1374.

13. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010;53 (3):542-550.

14. Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol. 2009;24 (3):443-452.

15. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117 (3):539-54

16. Lieber CS, Packer L. S-adenosylmethionine: molecular, biological, and clinical aspects - an introduction. Am J ClinNutr. 2002;76 (5):1148S-1150S.

17. Ou X, Yang H, Ramani K, Ara AI, Chen H, Mato JM, et al. Inhibition of human betaine-homocysteine methyl transferase expression by S-adenosylmethionine and methylthioadenosine. Biochem. J. 2007;401 (1):87-96.

18. Gil B, Casado M, Pajares MA, Bosca L, Mato JM, Martin-Sanz P, et al. Differential expression pattern of S-adenosylmethionine synthetases oenzymes during rat liver development. Hepatology. 1996;24 (4):876-881.

19. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol. 2011;26 (Suppl. 1):173-179.

20. Mato JM, Corrales FJ, Lu SC, Avila MA. S-adenosylmethionine: a control switch that regulates liver function. FASEB J. 2002;16 (1):15-26.

21. Song Z, Zhou Z, Chen T, Hill D, Kang J, Barve S, et al. S-denosylmethionine (SAMe) protects against acute alcohol induced hepatotoxicity in mice. J Nutr Biochem. 2003;14 (10):591-597.

22. Garcia-Ruiz C, Morales A, Colell A, Ballesta A, Rodes J, Kaplowitz N, et al.Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology. 1995;21(1):207-214.

23. Colell A, Garcia-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 1998;115(6):1541-1551.

24. Colell A, Garcнa-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodйs J, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and adenosyl- L-methionine. Hepatology. 1997;26 (3):699-708.

25. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 1989;24 (4):407-415

26. Finkelstein JD. Methionine metabolism in mammals. J NutrBiochem. 1990; 1:228-37. [PubMed: 15539209]

27. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975; 24:721-35. [PubMed: 1128236]

28. Cano A, Buqué X, Martínez-Uña M, Aurrekoetxea I, Menor A, García-Rodríguez JL, Lu SC, et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology. 2011; 54:1975-86. [PubMed: 21837751]

29. Elfhag K, Morey LC. Personality traits and eating behavior in the obese: poor self-control in emotional and external eating but personality assets in restrained eating. Eat Behav. 2008; 2008:285-93. [PubMed: 18549987]

30. Sutin A, Ferrucci L, Zonderman A, Terracciano A. Personality and obesity across the adult life span. J PersSoc Psychol. 2011; 101:579-92. [PubMed: 21744974]

31. Brummett BH, Babyak MA, Williams RB, et al. NEO personality domains and gender predict levels and trends in body mass index over 14 years during midlife. J Res Pers. 2006; 40:222-36.

32. Bodenlos J, Lemon S, Schneider K, August M, Pagoto S. Associations of mood and anxiety disorders with obesity: comparisons by ethnicity. J Psychosom Res. 2011; 71:319-24. [PubMed: 21999975]

33. Luppino F, de Wit L, Bouvy P, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67:220-9. [PubMed: 20194822]

34. Pagoto S, Bodenlos JS, Kantor L, et al. Association of major depression and binge eating disorder with weight loss in a clinical setting. Obesity (Silver Spring). 2007; 15:2557-9. [PubMed: 18070746]

35. Smith E, Hay P, Campbell L, Trollor JN. A review of the association between obesity and cognitive function across the lifespan: implications for novel approaches to prevention and treatment. Obes Rev. 2011; 12:740-55. [PubMed: 21991597]

36. Allan JL, Johnston M, Campbell N. Missed by an inch or a mile? Predicting the size of intentionbehaviour gap from measures of executive control. Psychol Health. 2011; 26:635-50. [PubMed: 21360414]

37. Spitznagel MB, Garcia S, Miller LA, et al. Cognitive function predicts weight loss after bariatric surgery. SurgObesRelat Dis. 2013; 9:453-9. [PubMed: 22133580]

38. Weinstein AA, Kallman Price J, Stepanova M, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics. 2011; 52:127-32. [PubMed: 21397104]

39. Linde JA, Simon GE, Ludman EJ, et al. A randomized controlled trial of behavioral weight loss treatment versus combined weight loss/depression treatment among women with comorbid obesity and depression. Ann Behav Med. 2011; 41:119-30. [PubMed: 20878292]

40. Pagoto S, Schneider KL, Whited MC, et al. Randomized controlled trial of behavioral treatment for comorbid obesity and depression in women: the be active trial. Int J Obes. 2013; 37:1-8.

41. Busch AM, Whited MC, Appelhans BM, et al. Reliable change in depression during behavioral weight loss treatment among women with major depression. Obesity (Silver Spring). 2013; 21: E211-8. [PubMed: 23592677]

42. Janicak PG, Lipinski JD, Comaty JE, et al. S-Adenosylmethionine: a literature review and preliminary report. Ala J Med Sci. 1988;25: 306-13.

43. Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine: a review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs. 1989;38:389-416.

44. Bressa GM. S-Adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. ActaNeurolScand. 1994;154: 7-14.

45. Brown R, Gerbarg P, Bottiglieri T. S-Adenosylmethionine in the clinical practice of psychiatry, neurology and internal medicine. ClinPract Intern Med. 2000;1:230-41.

46. D Mello C., Swain M. Liver-brain interactions in inflammatory liver diseases: Implications for fatigue and mood disorders. Brain, Behavior, and Immuniti. 2014, vol.35, pp.9-20.

47. Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D; as Work Group of the American Psychiatric Association Council on Research. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017;78(6): e656-e667. doi:10.4088/JCP.16r11113

48. Elliott C, Frith J, Day CP, Jones DE, Newton JL. Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up. Dig Dis Sci. 2013;58(8):2383-91. doi: 10.1007/s10620-013-2657-2

49. Chen SS, Yu KK, Huang C, Li N, Zheng JM, Bao SX, Chen MQ, Zhang WH. The characteristics and clinical outcome of drug-induced liver injury in a Chinese hospital: A retrospective cohort study. Medicine (Baltimore). 2016;95(34): e4683. doi: 10.1097/md.0000000000004683

50. Raikhelson K.L., Kondrashina E. A. Àdåmethionine in the treatment of fatigue in liver diseases: a systematic review. Therapeutic Archive. 2019; 91 (2): 134-142. (in Russ.) DOI: 10.26442/00403660.2019.02.000130@@ Райхельсон К. Л., Кондрашина Э. А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019. 91(2): 134-142

51. Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. Gastroenterology. 1990;99(1):211-5. doi: 10.1016/0016-5085(90)91250-a

52. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A field trial. CurrTher Res. 1999;60(6):335-48. doi: 10.1016/s0011-393x(99)80010-1

53. Di Perri T, Sacco T, Festi D. The SMACK Investigator Group. Ademetionine in the treatment of chronic hepatic disease. Gastroenterol Int. 1999;12(2):62-8.

54. Podymova SD, Nadinskaia MYu. Clinical trial of Heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome. Klinicheskaia Meditsina. 1998;76(10):45-8 (InRuss.)@@ Подымова С. Д., Надинская М. Ю. Оценка эффективности препарата Гептрал у больных хроническими диффузными заболеваниями печени с синдромом внутрипеченочного холестаза. Клиническая медицина. 1998;76(10):45-8

55. BaranovskyAYu, Raykhelson KL, Marchenko NV. Application of S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Klinicheskie Perspektivy Gastroenterologii, Gepatologii = Clin Perspect Gastroenterol Hepatol. 2010;9(1):3-10 (In Russ)@@ Барановский А. Ю., Райхельсон К. Л., Марченко Н. В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3-10


Для цитирования:


Корочанская Н.В., Дурлештер В.М., Басенко М.А. S-адеметионин в терапии неалкогольной жировой болезни печени (НАЖБП). Экспериментальная и клиническая гастроэнтерология. 2021;(7):68-73. https://doi.org/10.31146/1682-8658-ecg-191-7-68-73

For citation:


Korochanskaya N.V., Durleshter V.M., Bacenko M.A. S-ademetionine in the treatment of non-alcoholic fatty liver disease (NAFLD). Experimental and Clinical Gastroenterology. 2021;(7):68-73. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-191-7-68-73

Просмотров: 49


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)